There are essentially two scenarios in which it might be possible to consider the ACE-inhibitors obsolete medications, having been 'put out to pasture' by the angiotensin II receptor blockers. One scenario is based on the current penchant for 'evidence-based medicine', and the other is primarily based on a more fundamental issue: economics.
One of the most pervasive trends in medicine in the last 20 years has been the growth and wide acceptance of 'evidence-based medicine': the theory that medicine should adopt those practices and procedures which have been shown by clinical trials to result in improved outcomes for individuals with the disease in question. 19 This trend satisfies both the medical scientists (whose work in clinical trials largely forms the basis for widespread recommendations) and traditional (ie, 'conservative') physicians. Because clinical trials of a new treatment typically require many years for completion, 'older treatments' usually have a several-year advantage over 'newer treatments', based on the precepts of 'evidence-based medicine'. This situation is very well illustrated in the comparison of ACE-inhibitors and ARBs: the ACE-inhibitors have a 10-15 year lead in clinical trial data, with many studies showing (for instance) a major significant survival benefit among heart failure patients, such that a prominent editorial about one such trial anointed ACE-inhibitors the 'cornerstone of heart failure therapy'. 20 Although there have been some recent refinements to 'optimal' therapy for heart failure (which now often includes digoxin, a low-dose beta-blocker, 21, 22 and spironolactone 23 ), most current research in heart failure is being done with the blinded study medication being added to standard-of-care therapy (which nearly always includes an ACE-inhibitor). In fact, for many of the ongoing and currently-planned studies of ARBs in heart failure, it was considered unethical to 'deprive' patients of ACE-inhibitors, and instead give them the newer ARBs; as a result, several of the clinical trials are being conducted with all heart failure patients on an ACE-inhibitor, to which is added either placebo or an ARB. This situation essentially makes it impossible to obtain data supporting the use of an ARB alone as an effective treatment for heart failure (or any of the other disease states for which ACE-inhibitors are now so useful).
When (and if) current and future research proves that ARBs are at least as effective (if not more effective) than ACE-inhibitors for the prevention of morbidity and mortality, then the suggestion of the patient in the above vignette may be vindicated. Until then, a reasonable rebuttal to the suggestion would be that, 'We have clear data showing the benefits of the tablets I'm about to give you, in reducing the complications of high blood pressure. If you can take them without experiencing sideeffects, it is likely that they will improve your prognosis as they have improved the lot of patients who were given them in clinical trials. If you can't tolerate them, obviously we will be forced to try something else less well-proven. ' The second argument which can be marshalled by the health care provider in favour of using an ACEinhibitor rather than an ARB is based on economics. Perhaps because ACE-inhibitors have been seen as the most homogeneous of the 'traditional' antihypertensive drugs (as compared, for instance, to diuretics, beta-blockers, and calcium antagonists), many authorities see very little difference between the agents, except for those related to economics. The ACE-inhibitors are an excellent example of 'laissez-faire' economics: as the therapeutic class became more crowded, costs for these agents declined (see Figure 1) . Furthermore, generic captopril has become available at an average wholesale price of approximately US$0.04 per day to several health care plans with aggressive pharmacy benefits managers, which is competitive with other generic antihypertensive agents, and approximately 28 times cheaper than the currently-least expensive ARB. 24 Unfortunately, despite perhaps even greater homogeneity among the ARBs (even compared to ACEinhibitors), the ARBs have not shown a similar decrement in average wholesale prices in the USA (see Figure 2) ; the recommended starting dose of each is priced literally within pennies per day of the others. 24 This situation may improve when the sixth ARB is introduced (see Figure 1 ). There may be little coincidence that the ARBs were introduced just 24 about the time that the most popular ACE-inhibitors were at the end of their patent lives, and promoted by companies with large profits to lose when the ACE-inhibitor was no longer protected by patent. If (and when) the economics of acquiring an ARB are competitive with the cost of an ACE-inhibitor, there will be a greater interest among physicians, pharmacists, and the organizations that employ them, in allowing the health care consumer to receive these medications primarily.
In the USA, it is much more typical for the health care provider to use the economic argument to rebut the suggestion given by the consumer above. There are currently several methods that enterprising medical care systems have put into place to enforce the primary choice of ACE-inhibitors in this setting. It is common practice for ARBs to be dispensed only if the pharmacist has a record of a previous dispensing of an ACE-inhibitor, typically within the previous 90 days. To ensure that only patients with legitimate previous adverse effects with ACE-inhibitors (eg, angioedema or persistent dry cough) receive the more expensive drug, many pharmacy benefits managers require special forms to be completed before an ARB can be dispensed. Typically two physicians' signatures are required on the request for an ARB; some organizations mandate that the two physicians must have different Federal Tax ID numbers (so that they cannot be business partners or simply sign each others' forms without forming an independent assessment). These requirements have been put into place to ensure that the lessexpensive ACE-inhibitor, with proven benefits in preventing morbidity and mortality in clinical trials, will not be superceded by the ARBs despite fewer side-effects. 
